Business Context and Reporting Period
This Form 8-K Current Report was filed by Bone Biologics Corporation on February 26, 2016, covering material events occurring between February 22 and February 24, 2016. The Company, a Delaware corporation, reported the entry into several material definitive agreements involving equity sales, strategic distribution options, and debt financing.
Key Financial Metrics and Transactions
The filing details specific capital raising and strategic partnership activities rather than standard periodic financial performance metrics (e.g., revenue, net income, or operating cash flow).
- Equity Sales: The Company sold 731,707 shares to Musculoskeletal Transplant Foundation, Inc. (MTF) and 487,804 shares to Orthofix, Inc. at a price of $2.05 per share.
- Debt Financing: The Company issued a $2,000,000 Convertible Secured Term Note to Hankey Capital, LLC.
- Debt Terms: The Note bears interest at the prime rate plus 4.0% (minimum 8.5% per annum), matures on February 23, 2019, and is convertible at $1.58 per share.
- Warrant Issuance: A warrant for 1,898,734 shares was issued to Hankey Capital with an exercise price of $2.05, expiring February 23, 2021.
- Collateral: The Note is secured by collateral shares to maintain a loan-to-value ratio of no greater than 50%, plus all personal property and license agreements.
Material Changes and Strategic Agreements
Significant changes in the Company's capital structure and strategic partnerships were reported:
- MTF Relationship: MTF, whose CEO serves as the Company's Chairman, increased its stake. Prior to the transaction, MTF held approximately 30.61% of outstanding shares. Additionally, the Company secured an exclusive option to distribute MTF's Sygnal demineralized bone matrix product. Exercising this option would require the Company to grant MTF 700,000 shares.
- Orthofix Relationship: Orthofix, Inc. purchased 487,804 shares of common stock.
- Liquidity Impact: Proceeds from the $2,000,000 Convertible Note are designated for working capital and general corporate purposes.
Guidance, Risks, and Contingencies
The filing does not provide forward-looking financial guidance or management commentary on future earnings. Key contingencies and risks include:
- Option Exercise Contingency: The Company must exercise the Sygnal distribution option within the term of the Option Agreement; otherwise, MTF is free to enter into agreements with third parties regarding those rights.
- Debt Conversion Risk: Hankey Capital has the sole discretion to convert the $2,000,000 Note into common stock at $1.58 per share prior to maturity, which could result in significant dilution.
- Collateral Requirements: The Company must maintain specific collateral share levels to satisfy the 50% loan-to-value ratio, with adjustments required annually or upon partial prepayment.
Investor Verification Checklist
- Verify the total cash proceeds received from the MTF and Orthofix share purchases and the Convertible Note.
- Confirm the current ownership percentage of MTF following the February 22 transaction.
- Review the specific "Critical Terms" of the Sygnal distribution option to assess commercial viability.
- Assess the dilution impact of the potential conversion of the $2,000,000 Note and the exercise of the 1,898,734 warrants.
- Examine the collateral share agreement to understand the Company's current equity position held by Hankey Capital.